Drug Profile
NIK 616
Latest Information Update: 14 Feb 2008
Price :
$50
*
At a glance
- Originator Kowa Pharmaceutical
- Class Antiasthmatics
- Mechanism of Action Neurokinin 1 antagonists; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Nov 2006 Nikken Chemicals has been acquired by Kowa and is now called Kowa Pharmaceutical
- 29 Jan 2004 Preclinical trials in Asthma in Japan (PO)
- 29 Jan 2004 Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO)